This project analyzes a randomized phase III clinical trial evaluating the efficacy and safety of panitumumab combined with FOLFOX4 chemotherapy as a first-line treatment for metastatic colorectal cancer (mCRC). It includes survival analysis, adverse event assessment, and statistical modeling based on patient KRAS status.
-
Updated
Feb 23, 2025 - HTML